文献速递糖尿病

SGLT1与SGLT2抑制剂的研发进展

Development of SGLT1 and SGLT2 inhibitors.
PubMed 文献 · Diabetologia · 2018-08-22

本文综述SGLT1和SGLT2抑制剂的研发历程。SGLT1介导肠道膳食葡萄糖摄取,SGLT2负责肾脏大部分葡萄糖重吸收,SGLT1重吸收剩余部分。SLC5A1突变导致葡萄糖/半乳糖吸收不良,SLC5A2突变与糖尿相关。根皮苷是最初的SGLT1/2竞争性抑制剂,但因肠道副作用和半衰期短受限。自2013年首个SGLT2抑制剂获FDA批准以来,SGLT2抑制剂已成为2型糖尿病治疗的新基石,并对心血管系统(包括心力衰竭)和肾脏有益。

要点

  • SGLT1介导肠道膳食葡萄糖摄取,SGLT2负责肾脏大部分葡萄糖重吸收
  • SLC5A1突变导致葡萄糖/半乳糖吸收不良,SLC5A2突变与糖尿相关
  • SGLT2抑制剂自2013年获FDA批准后成为2型糖尿病治疗新基石

核心结论

  • SGLT2抑制剂已成为2型糖尿病治疗的新基石,并对心血管系统(包括心力衰竭)和肾脏有益。

研究设计与样本

  • 综述,聚焦SGLT2和SGLT1单药抑制剂及双重SGLT1/2抑制剂的研发依据,涵盖遗传学、基因修饰小鼠模型、数学建模及代谢领域药物发现的一般性考量。

主要发现

  • SGLT1介导肠道大部分膳食葡萄糖摄取;SGLT2负责肾脏小管系统中大部分葡萄糖重吸收,SGLT1重吸收滤过葡萄糖的剩余部分。
  • SLC5A1基因突变导致葡萄糖/半乳糖吸收不良,SLC5A2基因突变与糖尿相关。
  • 根皮苷是SGLT1和SGLT2的天然竞争性抑制剂,提供首个疗效概念验证,但受肠道副作用和半衰期短限制。
  • 自2013年首个SGLT2抑制剂获美国FDA批准以来,SGLT2抑制剂已成为2型糖尿病治疗的新基石。

临床怎么用

  • SGLT2抑制剂用于2型糖尿病治疗,并对心血管系统(包括心力衰竭)和肾脏有益。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sodium-glucose cotransporters SGLT1 (encoded by SGLT1, also known as SLC5A1) and SGLT2 (encoded by SGLT2, also known as SLC5A2) are important mediators of epithelial glucose transport. While SGLT1 accounts for most of the dietary glucose uptake in the intestine, SGLT2 is responsible for the majority of glucose reuptake in the tubular system of the kidney, with SGLT1 reabsorbing the remainder of the filtered glucose. As a consequence, mutations in the SLC5A1 gene cause glucose/galactose malabsorption, whereas mutations in SLC5A2 are associated with glucosuria. Since the cloning of SGLT1 more than 30 years ago, big strides have been made in our understanding of these transporters and their suitability as drug targets. Phlorizin, a naturally occurring competitive inhibitor of SGLT1 and SGLT2, provided the first insights into potential efficacy, but its use was hampered by intestinal side effects and a short half-life. Nevertheless, it was a starting point for the development of specific inhibitors of SGLT1 and SGLT2, as well as dual SGLT1/2 inhibitors. Since the approval of the first SGLT2 inhibitor in 2013 by the US Food and Drug Administration, SGLT2 inhibitors have become a new mainstay in the treatment of type 2 diabetes mellitus. They also have beneficial effects on the cardiovascular system (including heart failure) and the kidney. This review focuses on the rationale for the development of individual SGLT2 and SGLT1 inhibitors, as well as dual SGLT1/2 inhibition, including, but not limited to, aspects of genetics, genetically modified mouse models, mathematical modelling and general considerations of drug discovery in the field of metabolism.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia. 2018. PMID: 30132033. doi:10.1007/s00125-018-4654-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。